Skip to main content
VIVOZON PHARMACEUTICAL CO., LTD. logo

VIVOZON PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 082800 ISIN · KR7082800004 KO Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2024-01-31 Director's Dealing
Country KR South Korea
Listing KO 082800

About VIVOZON PHARMACEUTICAL CO., LTD.

https://www.vivozon.com/

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. It details the acquisition of shares by an executive (Choi Eungsup) of Vivozon Pharmaceutical. This type of filing is a standard regulatory disclosure for insider transactions, which corresponds to the 'Director's Dealing' category.
2024-01-31 Korean
주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean financial authorities regarding the 'Decision to Dispose of Treasury Shares' (자기주식 처분 결정). It details the company's plan to transfer treasury shares to an employee stock ownership association and provide special performance bonuses. Since the document specifically reports the company's action of disposing of its own shares (buyback/disposal), it falls under the 'Transaction in Own Shares' category.
2024-01-30 Korean
전환가액의조정(제20회차)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price for convertible bonds (CB). It details the change in conversion price, the number of convertible shares, and the underlying calculation methodology based on market price fluctuations. This type of disclosure is a standard capital structure update related to financing instruments, which falls under the 'Capital/Financing Update' category.
2024-01-22 Korean
전환가액의조정(제20회차)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price for convertible bonds (CB) due to a decline in market price. This type of disclosure is a standard corporate action related to capital structure and financing instruments. In the provided taxonomy, 'CAP' (Capital/Financing Update) is the most accurate category for updates on financing activities and adjustments to convertible debt instruments.
2023-12-20 Korean
전환사채(해외전환사채포함)발행후만기전사채취득(제20회차)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory disclosure regarding the acquisition of convertible bonds before maturity (Put option exercise). It details the bond series, acquisition amount, date, and the reason for the transaction (early redemption). This falls under capital structure and financing updates, specifically related to debt instruments.
2023-12-20 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 95% confidence The document is a short regulatory notice regarding the setting of a record date and shareholder register closure for an upcoming Annual General Meeting (AGM). It does not contain the full AGM materials or proxy statements, but rather serves as a formal regulatory notification of the administrative process for shareholder identification. Given it is a standard regulatory announcement regarding corporate governance procedures, it fits best under the RNS category.
2023-12-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.